We are pleased to invite you to attend GTCbio’s Infectious Diseases Summit, which will take place July 13-14, 2017 in Baltimore, MD. This event seeks to provide a forum for leaders to get the most comprehensive and wide-reaching perspective on issues, challenges, and advances in the field.
The Summit begins with the Plenary Session on Responding to Emerging Infectious Diseases on the Global Stage and disperses into the following three conferences:
6th Antiviral Drugs Research & Development
Respiratory Viral Infections: Current Landscape and Emerging Drugs
Blood Borne Pathogens: New Frontiers in Research and Drug Development
Regulatory Challenges on Clinical Study Design and Considerations
Panel: New Approaches to Antiviral Development
15th Vaccines Research & Development
Vaccines for Infectious Diseases-Old & New Challenges
Next-Generation Vaccine Technologies
Enhancing Immunity at Both Ends of the Age Spectrum
Panel: Clinical Trial Design During Epidemics
14th Anti-Infectives Partnering & Deal-Making
Non-Traditional Approaches and Technologies in Anti-Infectives
Regulatory Considerations for Drug Development
Economic Drivers Moving Drug Development Forward
Panel: Funding & Partnering with US Government Agencies
Panel: Pricing and P&T Committee’s Role in Determining Novel Antibiotic Usage
Panel: Pushing and Pulling-What Incentives Help Spark Innovation in Antibiotic Drug Discovery and Development?
The end of the Summit comes together with the General Session on Public/Private Partnerships in Support of Global Health.
In recent years, the field of infectious diseases has faced repeated challenges, and areas such as pricing and reimbursement, regulatory, and the discovery of novel antibiotics have yet to be overcome.
However, recent deals and the reemergence of big pharma in the space has signaled that the landscape of infectious diseases is shifting: why is there a renewed interest in this field? What will it mean for biotech companies, government agencies, and other players? This Summit seeks to highlight all stages of the field, from research and novel therapeutics, to commercialization aspects and market activity. Colleagues from academia, industry, and government will gather at the interface of infectious diseases drug development to address current issues and find solutions to move the field forward into the future.
We hope to see you in Maryland!